Theralase Technologies (TSE:TLT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theralase Technologies Inc. announced that their drug Ruvidar has outperformed Acyclovir in preclinical trials against Herpes Simplex Virus 1, demonstrating more effective viral destruction. The company is now exploring partnerships and licensing as they gear up for the commercial development of Ruvidar in a market expected to reach $71.1 billion by 2032.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.